AM-2233
Encyclopedic
Encyclopedic
Typical encyclopedia coverage. Cross-reference for important decisions.
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 27 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 27 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
Aliases: Cs-325
Summary
AM-2233 is a full CB1/CB2 agonist with sub-nanomolar affinity; overdose margins are extremely narrow. Weigh doses with a 0.1 mg-resolution scale or use volumetric dosing. CRITICAL WARNING: AM-2233 is notably associated with severe and persistent tinnitus (ringing in the ears), even at moderate doses, which may last for hours to days.
Dose Information
Dose basis. Smoked: Potency is extremely high (full CB1/CB2 agonist). Community-reported ranges only; human data are sparse. Use a 0.001 g-resolution scale or volumetrically dose to avoid over- or under-reading; TripSit provides a volumetric converter. Begin with an allergy test (β€0.25 mg) and wait a full 20β30 min before redosing because peaks can be delayed and stacking is a common cause of adverse events. These precautions are emphasized for synthetic cannabinoids due to very narrow safety margins and frequent poisonings with this class. Sources: TripSit HR tools; EUDA synthetic cannabinoid harm briefings. Oral: Lipophilic; absorption improves with fat/oil carriers (e.g., butter, cream, oils) per user/HR reports. Onset is slower and duration longer than inhalation; avoid redosing for at least 2 h. Community-reported ranges only; measure precisely or use volumetric dosing. Sources: DrugsβForum AMβ2233 wiki; TripSit HR tools. (Dose figures and this note are from Drugs.Wiki.)
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Smoked | 0.5-1mg | 1-2mg | 2-4mg | 4mg+ |
| Oral | 2-3mg | 3-5mg | 5-8mg | 8mg+ |
Sources
Smoked
Dose ladder — Drugs.WikiOral
Dose ladder — Drugs.WikiOnset, Duration & After-effects
| ROA | Onset | Peak | Offset | Total |
|---|---|---|---|---|
| Smoked | 1-2 min | 5-20 min | 30-90 min | 0.59-1.86 hrs |
| Oral | 15-45 min | 0.75-2 hrs | 30-90 min | 1.5-4.25 hrs |
Effect Profile
Scores (0–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Mild visuals, headspace, and auditory effects with moderate body load
Tolerance
Tolerance Decay
Tolerance to CB1-mediated effects can build within days of daily exposure and tends to remit over weeks; estimates extrapolated from cannabinoid class observations and user reports. Data quality is limited and highly variable between compounds and users.
Cross-Tolerances
Effects
Effect glossary — · full glossary
- Body lightness or heaviness
Combinations
Cross-Check AM-2233 with another substanceHelpful Links
Add to PsychonautWiki Journal
The PsychonautWiki Journal logging app doesn't include every substance. To track AM-2233 there, start adding an ingestion, search for the name, and choose to add it as a custom substance. Paste these values:
AM-2233 Source: SubstanceSearch (substancesearch.com) Smoked dose (mg): threshold 0.25 Β· light 0.5-1 Β· common 1-2 Β· strong 2-4 Β· heavy 4+ Oral dose (mg): threshold 1 Β· light 2-3 Β· common 3-5 Β· strong 5-8 Β· heavy 8+ Smoked duration: onset 1-2m Β· peak 5-20m Β· offset 0.5-1.5h Β· total 0.59-1.86h Β· after-effects 2-6h Oral duration: onset 15-45m Β· peak 0.75-2h Β· offset 0.5-1.5h Β· total 1.5-4.25h Β· after-effects 2-6h Note: ranges are harm-reduction guidance, not a prescription. Start low, go slow, and test your substances.
Tip: for quicker logging you can also add a Custom Unit in the app, e.g. common dose ~ 1.5 mg (Smoked).
The app keeps custom substances simple, so the full dose ranges live in the description text above. Ranges are harm-reduction guidance, not a prescription.
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for AM-2233? Let us know. Reports are reviewed by moderators — this is not posted publicly.